NVO · Novo Nordisk A/S
AI read · Neutral
The AI's read
The plans and Nanexa deal give Novo more ways to develop medicines beyond its current focus. But semaglutide is losing patent protection, competition is growing, and the company has not shown that new drugs will replace lost sales. The possible gains and the patent challenge point in different directions, so this story does not yet change the overall picture.